ReviewCost effectiveness and resource allocation : C/E2025
Clinical, humanistic, and economic burden of systemic lupus erythematosus in the Kingdom of Saudi Arabia.
Review in Cost effectiveness and resource allocation : C/E, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSystemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by abnormal immune system activity, primarily affecting the working-age population. The study aimed to evaluate SLE’s burden of disease from a societal perspective in the Kingdom of Saudi Arabia (KSA).
methodsThe burden of disease model was developed using Microsoft Excel® as the analytical tool for a one-year time frame. It was based on various inputs gathered through a literature review, input from key opinion leaders, and one-way sensitivity analysis, followed by local Delphi panel validation.
resultsThe overall economic burden of SLE proper, lupus nephritis, and lupus central nervous system (CNS) for one year amounted to SAR 46,187,056, SAR 78,776,030, and SAR 19,822,905, respectively. This condition resulted in 263.6 years lived with disability (YLD) and 251.1 years of life lost (YLL), resulting in a total of 514.7 disability-adjusted life years (DALYs), valued at SAR 58,768,258 for SLE proper. For lupus nephritis, the burden is 542.96 DALYs (232.12 YLD and 310.85 YLL), amounting to SAR 61,995,057 and 129.67 DALY (10.55 YLD and 119.12 YLL) valued at SAR 14,805,541 for lupus CNS. Event management cost was the primary contributor to the economic burden, followed by high drug acquisition cost, which also significantly adds to overall healthcare expenses. The introduction of biologics to the treatment of SLE is expected to curb the monetary losses due to the humanistic burden of the disease.
conclusionTo address the potential burden of SLE on the Saudi healthcare system, it is recommended to improve access to biologic therapies, enhance disease awareness, and implement targeted policy measures to support effective resource allocation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.